Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Phase II Trial of CLAG-M in Relapsed ALL

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01513603

Enrollment

Registered

2012-01-20

Start date

2012-01-31

Completion date

2014-01-31

Last updated

2012-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Lymphoblastic Leukemia, Burkitts Leukemia/Lymphoma, Chronic Myelogenous Leukemia, Lymphoblastic Lymphoma

Brief summary

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Detailed description

Patients will receive standard dose CLAG-M (cladribine, cytarabine, mitoxantrone, filgrastim). Standard support care will be given. Efficacy will be assessed through bone marrow examinations and blood tests.

Interventions

DRUGCLAG-M

IV times 5 days

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Relapsed or refractory acute lymphoblastic leukemia, * Burkitts leukemia/lymphoma, * Lymphoid blastic CML, * Lymphoblastic lymphoma.

Design outcomes

Primary

Measure	Time frame
Complete remission percentage	1 month

Secondary

Measure	Time frame
Survival	2 years

Countries

United States

Contacts

Primary ContactKaren Seiter, MD

karen_seiter@nymc.edu914 493 7514

Backup ContactNasir Ahmed, MD

nasir_ahmed@nymc.edu914 493 7514

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026